Abstract
A new series of 2-benzyl-6-(substituted phenyl)-imidazo[2,1-b][1,3,4] thiadiazoles (S1-S8) was synthesized as potential anti-cancer agents. These compounds were evaluated for their anticancer activity against various cancer cell lines. The anticancer activity data reveals that the compounds S1 (2-benzyl- 6-phenylimidazo[2,1-b][1,3,4]thiadiazole) showed maximum growth inhibition against CNS cancer cell lines while the compounds S2 (2-benzyl-6-(4-chlorophenyl) imidazo[2,1-b][1,3,4] thiadiazole) and S3 (2-benzyl-6-(2,4-dichlorophenyl)imidazo[2,1-b][1,3,4] thiadiazole) showed maximum inhibition against leukemia cell lines. The compounds S5 (2-(2-benzylimidazo[2,1-b] [1,3,4]thiadiazol-6-yl) phenol) and S6 (4-(2-benzylimidazo[2,1-b][1,3,4] thiadiazol-6-yl)benzene-1,3-diol) showed maximum inhibition against renal cancer cell lines and the compound S7 (3-(2-benzylimidazo[2,1-b][1,3,4] thiadiazol-6-yl) benzenamine) was most active against non-small cell lung cancer cell lines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
